Q1 2025 Earnings Forecast for Zymeworks Inc. (NYSE:ZYME) Issued By HC Wainwright

Zymeworks Inc. (NYSE:ZYME - Free Report) - Stock analysts at HC Wainwright cut their Q1 2025 earnings estimates for Zymeworks in a research note issued to investors on Wednesday, September 25th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($0.47) per share for the quarter, down from their prior estimate of ($0.45). HC Wainwright has a "Neutral" rating and a $12.00 price target on the stock. The consensus estimate for Zymeworks' current full-year earnings is ($0.85) per share. HC Wainwright also issued estimates for Zymeworks' Q2 2025 earnings at ($0.50) EPS, Q3 2025 earnings at ($0.53) EPS, Q4 2025 earnings at ($0.55) EPS and FY2025 earnings at ($2.05) EPS.

Separately, Stifel Nicolaus increased their price objective on shares of Zymeworks from $20.00 to $21.00 and gave the stock a "buy" rating in a report on Friday, August 2nd.

Zymeworks Price Performance

NYSE ZYME remained flat at $12.47 during trading hours on Friday. 126,910 shares of the company's stock were exchanged, compared to its average volume of 643,541. Zymeworks has a 12-month low of $6.01 and a 12-month high of $13.27. The stock has a market capitalization of $881.69 million, a PE ratio of -7.03 and a beta of 1.19. The stock has a 50 day simple moving average of $11.23 and a 200 day simple moving average of $9.93.

Zymeworks (NYSE:ZYME - Get Free Report) last released its quarterly earnings data on Thursday, August 1st. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.01. Zymeworks had a negative net margin of 179.42% and a negative return on equity of 21.97%. The company had revenue of $19.24 million during the quarter, compared to the consensus estimate of $23.16 million. During the same period in the previous year, the firm earned ($0.76) earnings per share.

Institutional Trading of Zymeworks

A number of institutional investors and hedge funds have recently modified their holdings of the company. Rubric Capital Management LP boosted its stake in Zymeworks by 31.1% in the fourth quarter. Rubric Capital Management LP now owns 3,475,384 shares of the company's stock valued at $36,109,000 after acquiring an additional 823,990 shares during the last quarter. Susquehanna Fundamental Investments LLC bought a new position in Zymeworks during the first quarter worth about $579,000. O Shaughnessy Asset Management LLC grew its holdings in Zymeworks by 51.5% during the first quarter. O Shaughnessy Asset Management LLC now owns 255,497 shares of the company's stock worth $2,688,000 after purchasing an additional 86,797 shares during the period. Affinity Asset Advisors LLC bought a new stake in shares of Zymeworks during the second quarter worth approximately $1,626,000. Finally, AlphaMark Advisors LLC bought a new stake in shares of Zymeworks in the first quarter valued at approximately $32,000. 92.89% of the stock is currently owned by institutional investors.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.